“The recent expansion of our TRACTr, TRACIr, and ARM development programs displays our ability to enact a strategy that attempts to both maximize the benefit and value of our current clinical programs, including JANX007, while continuing to advance other differentiated candidates in oncology and autoimmune disease,” said David Campbell, Ph.D., President and CEO of Janux. “We look forward to additional clinical data from JANX007 and JANX008 expected in the second half of 2025.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Janux Therapeutics reaches clinical milestone in Merck TRACTr collaboration
- Janux Therapeutics: Strategic Innovations and Robust Pipeline Drive Buy Rating
- Optimistic Buy Rating for Janux Therapeutics Driven by Strategic Pipeline and Diversification
- Janux Therapeutics Inc: Strategic Advancements and Strong Positioning in Oncology Drive Buy Rating
- Janux Therapeutics’ Strategic Expansion and Promising Pipeline Drive Buy Rating